Compare DLO & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLO | INDV |
|---|---|---|
| Founded | 2013 | N/A |
| Country | Uruguay | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.7B |
| IPO Year | 2021 | 2014 |
| Metric | DLO | INDV |
|---|---|---|
| Price | $14.21 | $34.85 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $17.25 | N/A |
| AVG Volume (30 Days) | ★ 1.8M | 1.5M |
| Earning Date | 05-14-2026 | 06-08-2026 |
| Dividend Yield | ★ 1.45% | N/A |
| EPS Growth | N/A | ★ 8100.00 |
| EPS | N/A | ★ 1.67 |
| Revenue | N/A | ★ $1,239,000,000.00 |
| Revenue This Year | $41.00 | N/A |
| Revenue Next Year | $26.98 | N/A |
| P/E Ratio | $22.27 | ★ $21.37 |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $10.64 | $22.30 |
| 52 Week High | $16.78 | $42.81 |
| Indicator | DLO | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 42.17 | 42.27 |
| Support Level | $13.28 | $32.06 |
| Resistance Level | $14.67 | $35.54 |
| Average True Range (ATR) | 0.43 | 0.86 |
| MACD | -0.13 | 0.17 |
| Stochastic Oscillator | 2.76 | 55.79 |
DLocal Ltd is focused on making the complex simple, redefining the online payment experience in emerging markets. Through its technology platform, One dLocal, the company enables world-wide enterprise merchants to get paid (pay-in) and to make payments (pay-out) online in a safe and efficient manner. The company earns revenue from fees charged to merchants in connection with payment processing services for cross-border and local payment transactions. The company operates in a single operating segment, which is payment processing. The company's geographical segments include Latin America and Non-Latin America, with a majority of its revenue being generated from Brazil in the Latin America region.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).